Liquidia stock may move 6.5% on Nov. 10 earnings release

Liquidia Corp. (LQDA) may see a 6.5% stock move on its Nov. 10 earnings release, according to options data. Past earnings moves have varied significantly from implied ranges, with both larger and smaller actual moves observed. The company reports before market open.

Original reporting
Published Nov 3, 2026, 3:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LQDANeutralMed
01

Why it matters

Traders may use the implied-move figure to size positions and set risk limits, but the historical track record suggests realized moves can deviate substantially.

02

Market read

This is a volatility and event-risk setup for LQDA into its earnings open, not a fundamental earnings disclosure.

03

What to watch

The article does not discuss consensus EPS/revenue, guidance expectations, or balance-sheet items, which often dominate earnings-day direction versus options-implied volatility.

Relevance 4/10Novelty 4/10Timing: Ahead of Nov. 10 pre-market earnings release for LQDA.

Background

The article frames LQDA’s Nov. 10 pre-market earnings as a volatility event using Bloomberg-compiled options-implied move history.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia (LQDA) is the earnings subject, with options-implied move cited for the Nov. 10 pre-market release.

Expected impact

Likely elevated volatility into the Nov. 10 open as traders position around the implied move, with direction uncertain given mixed historical accuracy.

Evidence & confidence

The piece provides an implied-move expectation for the upcoming print and shows prior instances where realized moves diverged materially from implied moves.

Market effects

Limited spillover; this is single-name earnings-volatility positioning rather than a sector catalyst.

Minimal, as it is a US small/mid-cap earnings setup.

Low, no cross-market or macro linkage beyond general risk appetite.

Counterpoint

Implied-move estimates can be systematically wrong, and the article’s own history shows both under- and over-shoots, so directional bets may be low edge.

Key entities

  • Liquidia Corp.

    NASDAQ-listed biotech whose Nov. 10 earnings are the focal event.

  • Bloomberg options data

    Used to estimate the implied move around the upcoming earnings release.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.